News

Auxilium has said that it plans to reallocate resources to its lead development project, AA4500, indicated for the treatment of Dupuytren's Contracture, a thickening of skin on the

As a recombinant therapy, NovoSeven is not plasma-derived and poses no risk of human viral transmission through its use. NovoSeven was first introduced in 1999. The FDA approved

RX-0201 is a first-in-class signal inhibitor that directly blocks the production of Akt, a protein kinase that plays a key role in cancer progression. The clinical trial of

AeroLEF is a unique inhaled-delivery system in development for the treatment of moderate to severe pain, including cancer pain. AeroLEF is designed to permit patients to match dosage

Introgen provided an update of data from several studies of the drug, including its effect on tumors and also on which patient populations were most likely to benefit

Januvia, manufactured by Merck, belongs to a new breakthrough class of prescription medications called DPP-4 inhibitors that improves blood sugar control in patients with type 2 diabetes. Januvia

Schering-Plough will be responsible for the development, manufacturing and commercialization of over-the-counter (OTC) products with the lower dosage strength of 20 mg for heartburn-related indications. Santarus will continue

Genzyme will acquire AnorMed in a cash transaction valued at $13.50 per outstanding share, or approximately $580 million. Genzyme started the bidding war in August with a hostile

The study used Optimata's computerized technology known as the Virtual Cancer Patient Engine (VCP). The trial was aimed at testing the accuracy of the VCP in predicting the